CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 1 filers reported holding CATABASIS PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $8,347,000 | -16.6% | 10,434,000 | 0.0% | 0.02% | -34.5% |
| Q2 2018 | $10,006,000 | +1631.1% | 10,434,000 | +6421.2% | 0.03% | +1350.0% |
| Q4 2016 | $578,000 | -14.9% | 160,000 | +45.1% | 0.00% | 0.0% |
| Q3 2016 | $679,000 | +52.9% | 110,250 | -8.1% | 0.00% | +100.0% |
| Q2 2016 | $444,000 | -26.6% | 120,000 | 0.0% | 0.00% | -50.0% |
| Q1 2016 | $605,000 | -4.6% | 120,000 | +50.0% | 0.00% | 0.0% |
| Q4 2015 | $634,000 | +56.5% | 80,000 | +60.0% | 0.00% | +100.0% |
| Q3 2015 | $405,000 | -33.7% | 50,000 | 0.0% | 0.00% | -50.0% |
| Q2 2015 | $611,000 | – | 50,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $10,573,000 | 10.68% |
| Clarus Ventures, LLC | 2,752,488 | $10,184,000 | 8.91% |
| Rhenman & Partners Asset Management AB | 345,100 | $1,277,000 | 0.23% |
| SPHERA FUNDS MANAGEMENT LTD. | 203,243 | $752,000 | 0.20% |
| Camber Capital Management LP | 1,000,000 | $3,700,000 | 0.18% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 643,580 | $2,381,000 | 0.09% |
| FT Options LLC | 15,059 | $56,000 | 0.05% |
| FRED ALGER MANAGEMENT, LLC | 86,782 | $321,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 27,700 | $102,000 | 0.00% |
| FIRST NEW YORK SECURITIES LLC /NY | 750 | $2,775,000 | 0.00% |